Iloprost Zentiva

Iloprost, the active ingredient in Iloprost Zentiva, is a prostacyclin analog presented as an inhalation solution for inhalation use. It is indicated for the management of pulmonary arterial hypertension in adult patients, where it helps to dilate the pulmonary arteries and reduce platelet aggregation, improving exercise capacity and symptoms.

GNH USA supplies Iloprost Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for specialized cardiovascular therapies.

Iloprost is used to treat conditions within the pulmonary hypertension disease family by providing targeted vasodilation.

- Pulmonary arterial hypertension: improves exercise capacity and delays disease progression. - Chronic thromboembolic pulmonary hypertension: reduces pulmonary vascular resistance and alleviates symptoms. - Pulmonary hypertension of other etiologies: provides vasodilation to improve oxygenation and functional status.

Iloprost may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Cough or throat irritation. - Headache. - Flushing or warmth sensation. - Nausea or dizziness.

Serious or Rare Side Effects: - Significant hypotension. - Pulmonary edema. - Bleeding events. - Severe bronchospasm.

When prescribing Iloprost, clinicians should observe several safety considerations to minimize risk.

- Monitor blood pressure: check for hypotension during initiation and dose adjustments. - Assess bleeding risk: avoid use in patients with active hemorrhage or uncontrolled anticoagulation. - Evaluate pulmonary function: watch for bronchospasm in patients with reactive airway disease. - Use cautiously after recent myocardial infarction: consider cardiac status before therapy. - Adjust in renal or hepatic impairment: dose may need modification based on organ function. - Store at room temperature: keep in original container, protect from moisture and light.

Iloprost can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Other potent vasodilators (e.g., nitroglycerin): additive hypotensive effect. - Endothelin receptor antagonists (e.g., bosentan): may enhance pulmonary vasodilation leading to low blood pressure.

Moderate Interactions (Monitor Closely): - Aspirin: may modestly increase bleeding tendency. - Calcium channel blockers: can potentiate blood pressure lowering.